1
Apr
2016

Medivation Under the Microscope, Obama’s Opioid Plan, & Burrill’s Ban

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery